Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly, the oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback